|
TM9SF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.1647800459782E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.4358964258513E-11 |
| Normal-vs-Stage2 |
2.213900E-02 |
| Normal-vs-Stage3 |
1.74416037168612E-13 |
| Normal-vs-Stage4 |
1.42470035768838E-10 |
| Stage1-vs-Stage2 |
3.150100E-02 |
| Stage1-vs-Stage3 |
3.056400E-02 |
| Stage1-vs-Stage4 |
3.486500E-02 |
| Stage2-vs-Stage3 |
1.659420E-03 |
| Stage2-vs-Stage4 |
1.383280E-03 |
| Stage3-vs-Stage4 |
6.202800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.70179450928754E-13 |
| Normal-vs-AfricanAmerican |
5.643300E-04 |
| Normal-vs-Asian |
6.22640000003116E-07 |
| Caucasian-vs-AfricanAmerican |
4.001400E-01 |
| Caucasian-vs-Asian |
4.337800E-01 |
| AfricanAmerican-vs-Asian |
8.153200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.50209869384821E-11 |
| Normal-vs-Female |
1.32959976362201E-10 |
| Male-vs-Female |
2.591200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.56470392198571E-11 |
| Normal-vs-Age(41-60Yrs) |
2.43890000417579E-08 |
| Normal-vs-Age(61-80Yrs) |
2.75940048588552E-10 |
| Normal-vs-Age(81-100Yrs) |
3.476200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.981400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.109800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.880400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.571400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.543600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.163000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.64360003174613E-10 |
| Classical-VS-Follicular |
1.963970E-01 |
| Classical-VS-Other |
2.256000E-01 |
| Classical-VS-Normal |
2.31500374425764E-11 |
| Tall-VS-Follicular |
2.27780000416899E-08 |
| Tall-VS-Other |
3.580800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.951590E-01 |
| Follicular-VS-Normal |
1.952820E-04 |
| Other-VS-Normal |
5.406800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.51270000029002E-07 |
| Normal-vs-N1 |
1.1576994918272E-10 |
| N0-vs-N1 |
5.115200E-03 |
|
|
